Scientists Identify Molecular Brake That Prevents Nerve Regeneration
Researchers at the Icahn School of Medicine at Mount Sinai have identified a molecular pathway that restricts how effectively neurons repair damaged axons after injury. Published in the journal Nature, the study reveals that a protein known as the aryl hydrocarbon receptor (AHR) acts as a cellular brake, forcing injured neurons to prioritize stress management over regenerative growth.
- The Molecular Brake: AHR signaling limits axon regrowth by prioritizing protein quality control (proteostasis) over the manufacture of new proteins needed for cellular repair.
- Experimental Recovery: Removing or pharmacologically blocking AHR in mouse models of peripheral nerve and spinal cord injury successfully promoted axonal regeneration and restored movement and sensation.
- Future Therapeutic Avenues: Because several drugs inhibiting AHR are already advancing through clinical trials for other conditions, researchers see a viable path toward repurposing these compounds for neural injuries.
Understanding the Axonal Regeneration Bottleneck in Mammalian Neurons
When axons—the long fibers responsible for transmitting signals across the central and peripheral nervous systems—are damaged or severed, functional recovery relies entirely on the neuron’s capacity to regrow these connections. In adult mammals, however, this intrinsic regenerative capacity remains severely constrained. Consequently, trauma to peripheral nerves or the spinal cord frequently results in permanent deficits in movement and sensation.
For years, the cellular mechanisms restricting this repair process puzzled investigators. According to findings detailed in the Nature publication, the core issue lies in how injured cells allocate their limited resources immediately following trauma.
The Cellular Trade-Off Between Survival and Repair
When neurons experience physical injury, they face an immediate physiological crisis. Hongyan Zou, MD, PhD, Professor of Neurosurgery and Neuroscience at the Icahn School of Medicine at Mount Sinai and the study’s senior author, explained the conflict that ensues within the cell.
“When neurons are injured, they must deal with stress while also trying to regrow their axons,” Dr. Zou stated. “We discovered that AHR functions like a brake that shifts neurons toward managing stress rather than rebuilding damaged connections.”
Additional analysis showed that active AHR signaling supports proteostasis, a protective mechanism maintaining protein quality control. While this response helps stressed cells survive the immediate aftermath of an injury, it simultaneously suppresses the synthesis of new proteins required to rebuild severed axons. When researchers removed AHR or administered pharmacological blockers, the neurons shifted priorities, upregulating protein production and activating pathways governed by HIF-1α, a key regulator of metabolism and tissue repair.
Clinical Implications and the Path Toward Patient Trials
Originally identified as a sensor for environmental toxins and xenobiotics, AHR clearly serves an internal regulatory role by integrating environmental and metabolic signals with neuronal repair pathways. Suppressing this protein in experimental models successfully improved both motor and sensory recovery.
Because multiple AHR-inhibiting drugs are already undergoing clinical evaluation for separate indications, researchers anticipate a shorter preclinical pathway for testing these compounds in neurotrauma settings. Before human trials can commence, however, investigators must establish optimal dosing regimens, evaluate treatment timing windows, and assess how AHR inhibition impacts auxiliary cell types involved in the neuroinflammatory response.
As research progresses, unlocking this molecular brake offers a promising foundation for future restorative therapies in neurotrauma.